[
  {
    "ts": null,
    "headline": "Viking Therapeutics: The Turning Point Is Not Here Yet",
    "summary": "Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma remains risky.",
    "url": "https://finnhub.io/api/news?id=13352d11da720b6f820b3d891efe5ba459d5c223aa5daaf2ec4bd3b9bb12ead0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737383698,
      "headline": "Viking Therapeutics: The Turning Point Is Not Here Yet",
      "id": 132431719,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2025836701/image_2025836701.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma remains risky.",
      "url": "https://finnhub.io/api/news?id=13352d11da720b6f820b3d891efe5ba459d5c223aa5daaf2ec4bd3b9bb12ead0"
    }
  },
  {
    "ts": null,
    "headline": "Merck: 3x Pipeline And Undervaluation Make It A Buy",
    "summary": "Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and strong financial performance.",
    "url": "https://finnhub.io/api/news?id=57384b74c92c75156d318cc3b34d261a52d6ce2a9f901c7ffdbc17d078ba828c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737361800,
      "headline": "Merck: 3x Pipeline And Undervaluation Make It A Buy",
      "id": 132430099,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2144601366/image_2144601366.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and strong financial performance.",
      "url": "https://finnhub.io/api/news?id=57384b74c92c75156d318cc3b34d261a52d6ce2a9f901c7ffdbc17d078ba828c"
    }
  },
  {
    "ts": null,
    "headline": "IYH: Healthcare Dashboard For January",
    "summary": "iShares U.S. Healthcare ETF has higher fees and lower performance. See why IYH is a top choice and learn about 10 cheaper healthcare stocks this January.",
    "url": "https://finnhub.io/api/news?id=86abfb300be5fe18fd5f0ffd4e4f143d62a99946668de83db5584543560aa5e1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737351767,
      "headline": "IYH: Healthcare Dashboard For January",
      "id": 132429429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "iShares U.S. Healthcare ETF has higher fees and lower performance. See why IYH is a top choice and learn about 10 cheaper healthcare stocks this January.",
      "url": "https://finnhub.io/api/news?id=86abfb300be5fe18fd5f0ffd4e4f143d62a99946668de83db5584543560aa5e1"
    }
  },
  {
    "ts": null,
    "headline": "High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent",
    "summary": "A list of high-quality dividend-growth stocks near 52-week lows, including Merck, Nike, J&J, Pfizer, and more. Click here to find out more about dividend stocks.",
    "url": "https://finnhub.io/api/news?id=d7a7418bb66926e3cccbef441a5b34b4efea62d322faf5482d48bbc9e25cdbb8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737349568,
      "headline": "High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent",
      "id": 132429268,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483054642/image_1483054642.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "A list of high-quality dividend-growth stocks near 52-week lows, including Merck, Nike, J&J, Pfizer, and more. Click here to find out more about dividend stocks.",
      "url": "https://finnhub.io/api/news?id=d7a7418bb66926e3cccbef441a5b34b4efea62d322faf5482d48bbc9e25cdbb8"
    }
  }
]